» Articles » PMID: 8651153

Laparotomy and Proximal Gastric Vagotomy in Zollinger-Ellison Syndrome: Results of a 16-year Prospective Study

Overview
Specialty Gastroenterology
Date 1996 Jun 1
PMID 8651153
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Pharmacological control of gastric acid hypersecretion in the Zollinger-Ellison syndrome has steadily improved, but medical treatment does not address the underlying tumor. The objective of this study was to evaluate the long-term effectiveness of a surgical approach to both tumor and acid hypersecretion in 22 patients with the Zollinger-Ellison syndrome.

Methods: Patients underwent laparotomy to resect tumors, combined with vagotomy to reduce acid secretion, followed by postoperative antisecretory therapy, if necessary.

Results: No surgical mortality or serious morbidity occurred. Tumor was found at laparotomy in nine patients (41%) and during long-term follow-up in an additional two patients (9%). Ten-year survival is 81%, with a long-term cure rate of at least 14%. Most patients (86%) have had long-term inhibition of acid secretion. Eight patients have discontinued regular use of acid-inhibiting medications. Patients requiring medication need less of it, and they have an improved acid inhibitory response to medication for up to 16 yr after surgery.

Conclusion: Cure of the Zollinger-Ellison syndrome is possible in a minority of patients. Acid secretion can be safely reduced in almost all patients with laparotomy/vagotomy, usually allowing discontinuation, or reduced dose, of acid-inhibiting drugs. Long-term survival and quality of life are generally excellent.

Citing Articles

Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.

Ito T, Ramos-Alvarez I, Jensen R Int J Mol Sci. 2024; 25(13).

PMID: 39000391 PMC: 11242121. DOI: 10.3390/ijms25137286.


Gastric Hypersecretory States: Investigation and Management.

Phan J, Benhammou J, Pisegna J Curr Treat Options Gastroenterol. 2015; 13(4):386-97.

PMID: 26342486 PMC: 4633316. DOI: 10.1007/s11938-015-0065-8.


Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.

Berna M, Hoffmann K, Serrano J, Gibril F, Jensen R Medicine (Baltimore). 2006; 85(6):295-330.

PMID: 17108778 PMC: 9806863. DOI: 10.1097/01.md.0000236956.74128.76.


Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.

Norton J, Jensen R Ann Surg. 2004; 240(5):757-73.

PMID: 15492556 PMC: 1356480. DOI: 10.1097/01.sla.0000143252.02142.3e.


Gastrinoma.

Li M, Norton J Curr Treat Options Oncol. 2002; 2(4):337-46.

PMID: 12057114 DOI: 10.1007/s11864-001-0027-3.